Safety Study of Stem Cell Treatment for NMOSD Relapse
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests whether a new stem cell treatment (CE211NS21) is safe and well-tolerated in patients who have had a recent serious attack from NMOSD, a rare neurological condition. The treatment aims to reduce disability and vision loss from this disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 19 and 65 years old
- You have been diagnosed with AQP4-IgG positive NMOSD (confirmed by blood test)
- You've had a severe relapse (attack) within the last 28 days with specific nerve damage in your spinal cord or optic nerve
- You have a blood relative (aged 19–70) who could serve as a bone marrow donor
- You are willing to use contraception for 12 months after receiving the treatment (if you could become pregnant or father children)
- You can attend clinic visits, either independently or with a caregiver
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called NouvSoma001 for neuromyelitis optica spectrum disorder (NMOSD), a condition where the immune system attacks the optic nerves and spinal cord. It looks at whether the drug is safe and helps people who have had a recent attack with severe pain, trouble walking, or bladder/bowel problems.
This study tests whether a new experimental medicine called CC-97540 is safe and well-tolerated in patients with a rare neurological disease called neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody marker (anti-AQP4). The trial involves a procedure that removes and reprocesses some of your immune cells.
This trial tests an antibody treatment for people having a neuromyelitis optica (NMO) relapse. It may reduce nerve damage from inflammation during an acute attack.
This study follows people with NMOSD (a rare autoimmune disease that can cause vision loss and paralysis) to learn more about the condition. It may help doctors better understand and treat NMOSD in the future.
This trial tests an investigational drug called B001 for people with NMOSD who have had recent relapses. The goal is to see if it can reduce future flare-ups.
This trial tests a drug called sivelestat to see if it can help people who are currently having a relapse of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. The study aims to find out if the drug is safe and if it reduces symptoms during a relapse.
Hear when a new Neuromyelitis Optica Spectrum Disorder Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.